New Republic16d
Trump’s Funding Freeze Creates Narco Dream at Mexico Border
Donald Trump’s freeze on foreign aid is hurting one of his major campaign promises: taking on fentanyl and ending overdose deaths from the drug in the ... of a MAGA plaque at a public library.
Medical Device Network on MSN1d
FDA clears Caristo’s AI-powered CAD diagnostic software
The software can determine the extent and severity of coronary plaque build-up implicated in coronary artery disease.
Nasdaq20d
Teva Pharmaceuticals and Alvotech Announce FDA Approval of SELARSDI™ Biosimilar for Multiple Indications
pediatric plaque psoriasis and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. market under the Teva and Alvotech strategic partnership. The FDA has ...
Morningstar10d
Elucid Adds Clinical and Commercial Leadership Ahead of PlaqueIQ™ Launch
Elucid’s PlaqueIQ is the first FDA-cleared non-invasive software that can objectively quantify and classify plaque morphology based on ground-truth histology, the gold standard for ...
Orange County Register24d
Trump administration cuts reach FDA employees in food safety, medical devices and tobacco products
WASHINGTON (AP) — The Trump administration’s effort to slash the size of the federal workforce reached the Food and Drug Administration this weekend, as recently hired employees who review the ...
AOL5d
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s
Leqembi has been shown to successfully reduce amyloid plaques in the brain. (It’s actually the second drug shown to do this; the first one was Aduhelm.) Amyloid plaque is a substance that may ...
Mena FN6d
Biocon Biologics Announces Positive Results From Phase 3 Study Of Yesintektm Biosimilar To Ustekinumab For Chronic Plaque Psoriasis
YESINTEK has been approved by the US FDA for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic ...
Nasdaq20d
Teva Pharmaceuticals and Alvotech Announce U.S. Launch of SELARSDI™ Biosimilar for Autoimmune Diseases
The U.S. Food and Drug Administration (FDA) has approved SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), for treating various conditions including plaque psoriasis ...
Yahoo Finance20d
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
pediatric plaque psoriasis and pediatric psoriatic arthritis. This is the second biosimilar now available in the U.S. market under the Teva and Alvotech strategic partnership. The FDA has ...
Yahoo19d
U of I Police officer awarded Badge 1 honor
38,858 people played the daily Crossword recently. Can you solve it faster than others?38,858 people played the daily Crossword recently. Can you solve it faster than others? Hunter Schafer’s ...
Pharmabiz23d
Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis
Bristol Myers Squibb announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...